Pain
Conditions
Keywords
Labour analgesia, Pregnancy, IVPCA
Brief summary
Epidural analgesia for pain relief in labor may not be suitable for all patients, and intravenous patient controlled analgesia (IV PCA) with opioids offers the best alternative. The purpose of this study is to assess the effectiveness of two methods remifentanil administration in the form of either an infusion or PCA demand bolus (intravenous injection of a single dose over a short period of time). Currently, our hospital gives remifentanil by demand bolus, however it may be equally effective, with less side effects, to give the drug as an infusion.
Detailed description
The study will be conducted as a randomized trial with two arms: Group I- continuous infusion of remifentanil with stepwise increase in infusion rates and Group II- demand bolus only with stepwise increase in bolus dose, as per the patient's analgesic requirement. Visual analog scores will be the primary outcome. Maternal and fetal side effects will be recorded. The results of this study will determine the regimen that suits the patients needs for painless labor with high efficacy, less adverse effects and a higher patient satisfaction.
Interventions
DRUGRemifentanil
Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min. Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
Sponsors
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent * Term pregnancy in labour with singleton fetus in cephalic presentation * Patients requesting systemic analgesia * Patients with contraindication for regional anesthesia without fetal compromise (coagulopathy, thrombocytopenia, refusal, etc.)
Exclusion criteria
* Refusal to sign written informed consent * Inability to communicate in English * Opioid dependence or addiction * Patients on Methadone * Allergy or hypersensitivity to remifentanil * Fetal heart rate abnormalities * Fetal congenital anomalies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | 24 hours | Verbal Numeric Rating Scale (VNRS) from 0 to 10 (where 0 = no pain and 10 = worst pain felt), approximately every hour, throughout labour. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maternal satisfaction | 24 hours | Maternal satisfaction rated from 0-10, throughout labour |
| Consumption of remifentanil | 24 hours | remifentanil consumed in mg/hr |
| Crossover to epidural | 24 hours | Time to crossover if the patient decides to have an epidural |
| Side effects | 24 hours | Sedation score, Heart Rate, Blood Pressure, Nausea, Vomiting, Pruritis |
| Fetal & Neonatal outcomes | 48 hours | Non-reassuring fetal heart rate as determined by obstetrician, Neonatal weight, Apgar scores, naloxone administration, need for resuscitation, NICU admission. |
Countries
Canada
Outcome results
None listed